Nicox S.A.
https://www.nicox.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nicox S.A.
VC Funding Dips In Q3, But 2024 Already Bests Full-Year 2023
Data from Evaluate show that biopharma venture capital investment fell from $7.95bn in Q2 to $6.59bn in Q3, but both outpaced every quarter in 2023 as the financial market recovery continues.
Deal Watch: Shionogi Will Market Nxera’s Insomnia Drug In Japan
Plus deals involving Jiangsu Alphamab/CSPC, Zydus/CDRI, Junshi/JSIAMA, Repair/Genevant, Sanofi/I-Mab, Novartis/Mitem and BioAtla/Context.
Newron Weighs Up Partners Or M&A As Excitement Grows Over Antipsychotic
The Italian firm has received "several indications of interest" in evenamide, which is being prepped to go into Phase III for treatment-resistant schizophrenia.
Finance Watch: Bain Capital Raises $3bn For Fourth Life Sciences Fund
Private Company Edition: Bain will invest across private and public drug, device, diagnostic and tool companies. Also, Candid debuted with $370m in initial funding, Superluminal closed a $120m series A round, PanTera raised €93m ($102.4m) in series A cash and F2G brought in $100m.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
-
Drug Delivery
- Topical Delivery
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Laboratoires Doliage
- Eupharmed srl
- Aciex Therapeutics, Inc.
- AVEye Biotechnologie GmbH
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice